← Back to patent-cliff list
Budesonide Delayed-Release Tablets(Triastek)
Tier C — Watch / tradeBudesonide Delayed-Release Tablets(Triastek)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GR
Indications (approved)：免疫球蛋白a肾病
Regional status
US
-
EU
-
China
Phase II
2025-12-16
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Budesonide Delayed-Release Tablets(Triastek)?
Approved indications include: 免疫球蛋白a肾病.
When does the Budesonide Delayed-Release Tablets(Triastek) patent expire?
No public expiry year is available for Budesonide Delayed-Release Tablets(Triastek) yet; this page updates once verified.
How do I get a quote for Budesonide Delayed-Release Tablets(Triastek) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29